We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$206M
Cap. Flow
+$79.9M
Cap. Flow %
10.7%
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16

Top Buys

1
ALKS icon
Alkermes
ALKS
+$15.6M
2
STAA icon
STAAR Surgical
STAA
+$15.2M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.8M
4
LNTH icon
Lantheus
LNTH
+$12.5M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$11.4M

Top Sells

1
AGN
Allergan plc
AGN
+$16.2M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.6M
3
NVRO
NEVRO CORP.
NVRO
+$12.9M
4
WMGI
Wright Medical Group Inc
WMGI
+$12.8M
5
ABBV icon
AbbVie
ABBV
+$11.7M

Sector Composition

1 Healthcare 46.84%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Broadfin Capital deployed $79.9M of net new capital in Q4 2019, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 54% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $13.6M trimmed.

  • Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
  • Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
  • Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
  • Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
  • Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
  • Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
  • Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.